BiolineRX Ltd. (TASE:BLRX) today announced positive interim results in the Phase I/II clinical trial of its BL-5010 cream for the non-invasive treatment of seborrheic keratosis - noncancerous benign skin growths.
The safety and effectiveness trial in Germany and the Netherlands includes 60 patients. The goal of the trial is to test whether BL-5010 can remove the growths, without the need of surgery, without affecting healthy tissue. The trial also wants to test whether the drug can preserve the growths for histology tests (microscopic tests of the skin tissue).
The trial's interim results on 25 patients found that BL-5010 removed the seborrheic keratosis within 30 days from the start of treatment, and that the treatment was safe with no side effects, such as itchiness or inflammations. Most of the doctors and patients said that they were very satisfied with the cosmetic results of the trial.
BiolineRX said that BL-5010 is a non-invasive treatment for growths that does not cause infections or require anesthesia or bandages. The cream is rubbed into the growth for several minutes. BL-5010 removes the wart by drying the growth, leadin it to fall off after one to three weeks.
BiolineRX's share rose 3.5% in morning trading to NIS 4.20.
Published by Globes [online], Israel business news - www.globes-online.com - on January 27, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010